Last updated: September 3, 2026
Caffeine and ergotamine tartrate is a legacy oral migraine product historically marketed as Cafergot. Its U.S. commercial position has deteriorated because the product has no meaningful remaining exclusivity, its original formulation is operationally difficult to manufacture, and triptans and CGRP-targeted therapies have displaced ergotamine in routine migraine treatment. The combination has negligible publicly identifiable standalone revenue in the United States, no biosimilar exposure, limited patent leverage, and a primarily residual international market.
What is caffeine and ergotamine tartrate?
Caffeine and ergotamine tartrate is an oral combination used for the acute treatment of migraine attacks, with or without aura. Ergotamine produces vasoconstriction and interacts with serotonin receptors, while caffeine increases gastrointestinal absorption and may enhance ergotamine activity.
The historical U.S. reference product was Cafergot, supplied as tablets containing:
| Component |
Amount per tablet |
| Ergotamine tartrate |
1 mg |
| Caffeine |
100 mg |
The product is distinct from dihydroergotamine, including Migranal nasal spray and injectable D.H.E. 45. Dihydroergotamine has a different molecular structure, dosing profile and regulatory history.
The combination has a narrow therapeutic window. Product labeling limits the maximum daily and weekly dose and contraindicates use with potent CYP3A4 inhibitors because of the risk of severe peripheral ischemia, gangrene and other ergot toxicity [1].
What is the FDA status of Cafergot and related products?
The U.S. regulatory position is commercially weak. The FDA approved Cafergot under NDA 008175 in 1948. The product was later listed as discontinued in U.S. FDA databases. A discontinued listing does not necessarily mean that the FDA withdrew approval for safety or efficacy reasons; it generally indicates that the product is no longer being marketed under the relevant application [2].
U.S. regulatory timeline
| Event |
Approximate date |
Commercial implication |
| Cafergot approved under NDA 008175 |
1948 |
Established the original U.S. reference product |
| Ergotamine-caffeine marketed by multiple manufacturers and licensees |
Mid-20th century to early 2000s |
Fragmented generic and authorized-generic supply |
| Triptans introduced |
1990s |
Reduced use of ergotamine products |
| CGRP monoclonal antibodies and gepants introduced |
2018 onward |
Further reduced clinical relevance of legacy acute therapies |
| Cafergot U.S. marketing discontinued |
FDA database period |
Removed the original product from active commercial competition |
| Current U.S. market |
Limited or absent branded supply |
No major public revenue base attributable to the combination |
The FDA’s Orange Book is not a source of current commercial value for this product. Any historic listed patents would have expired long ago, and the discontinued reference product does not provide a meaningful modern reference-product barrier.
What patents protect caffeine and ergotamine tartrate?
No commercially important, unexpired U.S. patent estate is associated with the historic caffeine and ergotamine tartrate tablet.
The original product was approved more than 75 years ago. Any composition, dosage or conventional tablet patents associated with the original product have expired. The active ingredients are old small molecules, and the combination does not present the type of new chemical entity, biologic, device or complex manufacturing platform that can sustain late-life exclusivity.
Patent estate assessment
| Patent category |
Current assessment |
Business effect |
| Active ingredient patents |
Expired |
No molecule-level exclusivity |
| Original combination patents |
Expired or commercially irrelevant |
No barrier to generic replication |
| Conventional tablet formulation patents |
Expired |
Low formulation differentiation |
| Method-of-use patents |
No material active U.S. protection identified for the legacy product |
Limited enforcement leverage |
| Manufacturing patents |
No publicly significant blocking estate identified |
Supply depends on economics and know-how |
| Orphan-drug exclusivity |
Not applicable |
No seven-year exclusivity |
| Biologic exclusivity |
Not applicable |
No biosimilar framework |
| Pediatric exclusivity |
No current commercial relevance |
Does not extend market protection |
The principal intellectual-property risk is therefore not patent infringement. It is the opposite: manufacturers have little incentive to maintain production because generic competition limits pricing while ergotamine handling, quality control and regulatory compliance increase operating complexity.
When did caffeine and ergotamine tartrate lose exclusivity?
The combination lost practical exclusivity decades ago. The active ingredients were known before modern U.S. drug-exclusivity regimes, and the original tablet has no current new chemical entity exclusivity, orphan exclusivity or meaningful patent term.
Unlike recently approved small-molecule drugs, the product does not have a predictable “patent cliff” in the 2020s or 2030s. Its exclusivity cliff occurred historically. Current commercial erosion reflects product obsolescence and supply withdrawal rather than a new wave of patent-expiry-driven generic entry.
Are there Paragraph IV challenges to caffeine and ergotamine tartrate?
No material current Paragraph IV event is associated with an active U.S. Cafergot patent estate.
Paragraph IV litigation is generally relevant where a branded reference product has unexpired Orange Book patents and a generic applicant seeks approval before those patents expire. That framework has little commercial significance for discontinued Cafergot because:
- The principal patents are historic.
- The product is no longer a major active branded reference product.
- There is no valuable late-life patent position to defend.
- Generic substitution, where available, is driven by supply and clinical demand rather than a contested patent launch.
A generic applicant could still face regulatory questions involving product equivalence, inactive ingredients, bioavailability and manufacturing controls. Those are approval and quality issues, not evidence of a durable patent moat.
What formulations are protected by caffeine and ergotamine tartrate patents?
The conventional immediate-release tablet is not protected by a material current U.S. formulation estate. Its formulation is technically simple relative to extended-release, transdermal, inhaled or device-enabled drug products.
Formulation and manufacturing considerations
The commercial challenges are operational:
- Ergot alkaloids require tight potency and impurity controls.
- Dose uniformity is important because the therapeutic index is narrow.
- Caffeine can affect dissolution and absorption.
- Product stability and light or moisture protection must be controlled.
- Manufacturing volumes are low compared with common migraine drugs.
- Regulatory maintenance costs can exceed expected product margin.
These factors can create a practical manufacturing barrier without creating enforceable patent protection. A manufacturer may leave the market because production is uneconomic even when a competitor could legally enter.
How strong is the patent estate compared with modern migraine drugs?
Caffeine and ergotamine tartrate has one of the weakest patent positions in the migraine market. Modern competitors have used composition-of-matter patents, formulation patents, device claims, method-of-use claims and pediatric or regulatory exclusivities.
| Product or class |
Representative companies |
Principal protection profile |
Relative strength |
| Caffeine/ergotamine tartrate |
Historic Novartis and generic manufacturers |
Expired legacy rights |
Very weak |
| Sumatriptan |
GlaxoSmithKline and generic manufacturers |
Historic composition and formulation rights, now expired |
Weak commercially |
| Ubrogepant |
AbbVie |
Active composition, formulation and method-of-use claims during the 2020s |
Strong |
| Rimegepant |
Pfizer, formerly Biohaven |
Active composition, formulation and method-of-use rights |
Strong |
| Atogepant |
AbbVie |
Active composition and method-of-use rights |
Strong |
| Lasmiditan |
Eli Lilly and generic manufacturers |
More recent small-molecule patent estate |
Moderate to strong |
| Erenumab |
Amgen and Novartis |
Biologic patents and regulatory exclusivity |
Strong |
| Fremanezumab |
Teva |
Biologic patents and regulatory exclusivity |
Strong |
| Galcanezumab |
Eli Lilly |
Biologic patents and regulatory exclusivity |
Strong |
The comparison is commercially important. Ergotamine products compete largely on price and availability, while newer products compete on tolerability, contraindication profile, convenience and payer positioning.
What is the competitive landscape for ergotamine products?
Ergotamine has been displaced across most migraine-treatment segments.
Acute migraine treatment
The main alternatives are:
- Triptans, including sumatriptan, rizatriptan, eletriptan and zolmitriptan.
- Gepants, including ubrogepant and rimegepant.
- Lasmiditan.
- Nonsteroidal anti-inflammatory drugs and combination analgesics.
- Dihydroergotamine for selected refractory patients.
Triptans offer a more standardized modern treatment pathway. Gepants avoid vasoconstriction and are relevant for patients with cardiovascular contraindications to triptans and ergot alkaloids. CGRP-targeted preventive therapies also reduce the frequency of attacks requiring acute rescue treatment.
Clinical disadvantages
Ergotamine and caffeine have several commercial disadvantages:
- Vasoconstriction limits use in patients with cardiovascular disease.
- Drug interactions are significant.
- Nausea and vomiting can reduce adherence.
- Overuse can contribute to medication-overuse headache.
- Dosing is less convenient than newer oral acute therapies.
- The product lacks a major branded promotional platform.
- Supply interruptions can make treatment continuity difficult.
These disadvantages limit the ability of a manufacturer to raise price or invest in demand generation.
What is the financial trajectory of caffeine and ergotamine tartrate?
The financial trajectory is a long-term decline from a formerly established prescription product to a niche or discontinued generic therapy. No major public company reports standalone global revenue for caffeine and ergotamine tartrate. The product is generally grouped within broader mature-products, established-brands or generic portfolios.
Financial profile
| Metric |
Assessment |
| Historical revenue |
Not publicly disclosed as a standalone line item |
| Current U.S. branded revenue |
No material active branded revenue identified |
| Generic revenue |
Fragmented, low-volume and manufacturer-specific |
| Pricing power |
Very low |
| Patent-driven margin |
None |
| Manufacturing economics |
Vulnerable to low volume and compliance costs |
| Market growth |
Structurally negative in developed markets |
| Licensing value |
Low for the legacy tablet; potentially higher only for differentiated delivery |
| Investment case |
Niche supply opportunity, not a conventional growth asset |
The combination is unlikely to generate meaningful revenue through brand expansion. Any financial value would depend on a supply shortage, a geographic market where ergotamine remains standard care, or a differentiated formulation with improved tolerability and delivery.
A generic supplier could earn temporary margin during constrained supply, but this would be a procurement opportunity rather than a durable market position. The absence of patent protection means that price improvements could attract competition, provided another manufacturer can satisfy regulatory and manufacturing requirements.
Which companies are challenging or replacing ergotamine products?
The competitive pressure comes primarily from manufacturers of newer migraine therapies, not from patent challengers.
AbbVie has a broad migraine franchise spanning ubrogepant and atogepant. Pfizer markets rimegepant after acquiring Biohaven’s portfolio. Eli Lilly markets galcanezumab and previously commercialized lasmiditan. Amgen and Teva have major CGRP antibody products. Generic manufacturers compete with older triptans and analgesics.
The commercial substitution pattern is clear:
- Triptans replaced much of the routine ergotamine market.
- Gepants expanded treatment options for patients with cardiovascular limitations or triptan intolerance.
- Preventive CGRP therapies reduced acute-treatment frequency in high-burden patients.
- Ergotamine remained concentrated in specialist, refractory or geographically limited use.
What litigation and settlement agreements affect the product?
No significant current U.S. patent litigation or settlement agreement is central to the commercial outlook for caffeine and ergotamine tartrate.
Historic disputes may have involved product approval, marketing rights, manufacturing arrangements or generic substitution, but they do not create a present exclusivity barrier. The product’s litigation profile is materially different from that of newer migraine medicines, where patent settlements can determine generic entry dates and billions of dollars in revenue exposure.
What generic entry risks exist for caffeine and ergotamine tartrate?
Generic entry risk is high in legal terms but muted in commercial terms because the market is already largely generic or discontinued.
Generic launch scenarios
| Scenario |
Probability assessment |
Market effect |
| New conventional tablet entrant |
Legally feasible, commercially limited |
Adds supply but may not expand demand |
| Re-entry after shortage |
Possible |
Temporary price and volume increase |
| Branded relaunch |
Unlikely without a differentiated product |
High marketing and regulatory burden |
| New oral formulation |
Possible but weakly protected unless novel |
Could improve convenience, but faces newer competitors |
| Nasal or nonoral delivery |
Technically more differentiated |
Competes with established DHE and modern acute products |
| Broad market recovery |
Unlikely |
Clinical substitution remains structural |
The key risk to an incumbent is not an abrupt patent-triggered launch. It is chronic erosion caused by low demand, intermittent availability and substitution by newer therapies.
Does caffeine and ergotamine tartrate have biosimilar risk?
No. Caffeine and ergotamine tartrate is a synthetic small-molecule combination, not a biologic. Biosimilar approval pathways, biologic reference-product exclusivity and interchangeability rules do not apply.
Competition occurs through abbreviated new drug applications, conventional generic applications or country-specific equivalent-product procedures.
What geographic markets still support ergotamine demand?
Demand is more likely to persist in markets where:
- Older migraine treatment guidelines remain in use.
- Triptans or gepants are less affordable.
- Generic ergotamine is reimbursed.
- Specialist access to newer CGRP therapies is limited.
- Local manufacturers can produce small batches economically.
The U.S., Western Europe and other high-income markets have experienced the strongest substitution pressure. Emerging markets may retain demand, but the product’s low price and fragmented distribution make market size difficult to quantify from public filings.
Geographic opportunity is therefore supply-led. A manufacturer with an established regulatory network and low-cost production could maintain a niche position, but the addressable market is unlikely to support large-scale investment without a new delivery or combination strategy.
What is the revenue exposure for manufacturers and investors?
Revenue exposure to caffeine and ergotamine tartrate is generally immaterial for diversified pharmaceutical companies. A manufacturer’s risk is more likely to involve:
- Product discontinuation costs.
- Inventory write-offs.
- Regulatory maintenance expenses.
- Contract-manufacturing commitments.
- Shortage-related reputational risk.
- Portfolio complexity from low-volume legacy products.
For investors, the product should not be valued as a growth asset or as a patent-cliff event. Its potential value is limited to a specialty generic platform, a supply-constrained market, or an intellectual-property strategy involving a genuinely differentiated formulation.
Key Takeaways
- Caffeine and ergotamine tartrate is a legacy acute migraine combination historically sold as Cafergot.
- The U.S. product was approved in 1948 and has no meaningful current patent or regulatory exclusivity.
- Cafergot is listed as discontinued in FDA records, and standalone U.S. branded revenue is not materially identifiable.
- There is no meaningful active Paragraph IV or patent-litigation story tied to the legacy product.
- The product has no biosimilar risk because it is a synthetic small-molecule combination.
- Triptans, gepants, lasmiditan and CGRP preventive therapies have structurally reduced demand.
- Financial prospects are limited to niche generic supply, shortage-driven sales or a differentiated delivery system.
- Manufacturing complexity and low volume are more important barriers than intellectual property.
- A conventional relaunch would face weak pricing power and strong clinical substitution.
- The product’s commercial trajectory is decline, not a conventional patent-cliff recovery.
FAQs
Is caffeine and ergotamine tartrate still sold in the United States?
The historic Cafergot product is listed as discontinued in U.S. FDA records. Availability of equivalent products can vary by manufacturer, pharmacy inventory and jurisdiction.
Is ergotamine tartrate stronger than sumatriptan?
The products cannot be ranked simply by strength. Sumatriptan has a more standardized modern dosing profile, while ergotamine has a longer and more complex pharmacologic effect with greater vasoconstrictive and interaction-related limitations.
Can a company obtain new patents on an ergotamine-caffeine product?
A conventional tablet would face serious patentability challenges because the active ingredients and basic combination are old. A novel delivery system, formulation, dosing regimen or manufacturing process could support patent claims if it satisfies applicable novelty and inventive-step requirements.
Does ergotamine have a role after CGRP drugs fail?
It can remain a rescue option in selected patients, particularly where other acute therapies are ineffective or unavailable. Its use is constrained by cardiovascular contraindications, drug interactions and tolerability.
Why would a generic manufacturer discontinue an unpatented migraine drug?
Low volume, manufacturing controls, raw-material constraints, regulatory expenses and weak pricing can make an unpatented product commercially unattractive even when legal competition is unrestricted.
References
- U.S. Food and Drug Administration. (2013). Cafergot label: Ergotamine tartrate and caffeine tablets. FDA. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Cafergot, NDA 008175. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211. https://doi.org/10.1177/0333102417738202
- Dodick, D. W. (2018). A phase-by-phase review of migraine pathophysiology. Headache, 58(Suppl. 1), 4-16. https://doi.org/10.1111/head.13300
- U.S. Food and Drug Administration. (2024). Orange Book patent and exclusivity information. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
- AbbVie Inc. (2023). Annual report. https://www.abbvie.com/investors/financial-reports-and-filings.html
- Pfizer Inc. (2023). Annual report. https://www.pfizer.com/investors/financial-information/annual-reports
- Eli Lilly and Company. (2023). Annual report. https://investor.lilly.com/financial-information/annual-reports-and-proxy-statements
